-Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant-
QUEBEC CITY, and
April 9, 2013
Medicago Inc. (TSX: MDG); (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs) and, IDRI (Infectious Disease Research Institute), a
-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress. The meeting is being held at the Gaylord National Hotel and Convention Center in
April 16-18, 2013
, Founder, President, & Chief Scientific Officer, IDRI, and Dr.
, Professor of Medicine & Microbiology,
, member of Medicago's scientific advisory committee, will be presenting at the World Vaccine Congress on
April 17, 2013
2:35 p.m. EST
. The presentation, titled "H5N1 Phase 1 clinical trial combining Medicago's VLP vaccine with IDRI's GLA adjuvant formulation," will discuss preliminary safety and immunology data from the ongoing H5N1 vaccine clinical trial.
The Phase I clinical trial, which commenced in
, enrolled 100 healthy adult volunteers, aged 18-49 years, at three locations in the U.S., testing for safety and immune response. The vaccine was also tested in comparison to Medicago's H5N1 vaccine with alum. The trial is funded by a multi-million dollar grant IDRI received from the Defense Advanced Research Projects Agency (DARPA), a division of the United States Department of Defense, to investigate the safety and immunogenicity of a novel adjuvant with a
produced vaccine candidate. Each study participant in the trial received two doses of a given formulation in order to collect and compare data.
The trial focused on evaluating the safety and immunogenicity of the H5N1 vaccine, combined with IDRI's Glucopyranosyl Lipid A ("GLA") adjuvant, which was administered intramuscularly or intradermally. The intradermal route of administration was also tested in comparison with intramuscular delivery, using an FDA licensed device (MicronJet600®, NanoPass Technologies) as the micro-needle device was previously shown in seasonal and pandemic flu tests to allow significant dose sparing. This study is among the first to test intradermal adjuvants.